Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum.

Literature DB >> 7542394

Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum.

Abstract

The effects of the MAO-B inhibitors, L-deprenyl and MDL-72974 on MDMA-induced serotonergic neurotoxicity in rats were examined. MDMA alone produced a significant decrease in the number of 5-HT uptake sites, measured as a decrease in the Bmax for binding of [3H]paroxetine, and in 5-HT and 5-HIAA levels in the striatum. L-Deprenyl and MDL-72974 attenuated this MDMA-induced decrease in serotonergic markers. The data suggest a key role for MAO-B in the expression of the neurotoxicity produced by MDMA in the striatum.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1995 PMID： 7542394 DOI： 10.1007/bf02245967

Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN： 0033-3158 Impact factor: 4.530

12 in total

1. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.

Authors: D M Stone; M Johnson; G R Hanson; J W Gibb
Journal: J Pharmacol Exp Ther Date: 1988-10 Impact factor: 4.030

2. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues.

Authors: J F Nash; D E Nichols
Journal: Eur J Pharmacol Date: 1991-07-23 Impact factor: 4.432

3. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.

Authors: G Battaglia; S Y Yeh; E O'Hearn; M E Molliver; M J Kuhar; E B De Souza
Journal: J Pharmacol Exp Ther Date: 1987-09 Impact factor: 4.030

4. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.

Authors: C J Schmidt; C K Black; V L Taylor
Journal: Eur J Pharmacol Date: 1991-10-02 Impact factor: 4.432

5. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan.

Authors: J E Sprague; X Huang; A Kanthasamy; D E Nichols
Journal: Life Sci Date: 1994 Impact factor: 5.037

6. Distinct monoamine oxidase A and B populations in primate brain.

Authors: K N Westlund; R M Denney; L M Kochersperger; R M Rose; C W Abell
Journal: Science Date: 1985-10-11 Impact factor: 47.728

7. The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin.

Authors: U V Berger; R Grzanna; M E Molliver
Journal: Brain Res Date: 1992-04-24 Impact factor: 3.252

8. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis.

Authors: J F Nash
Journal: Life Sci Date: 1990 Impact factor: 5.037

9. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.

Authors: C J Schmidt; V L Taylor
Journal: Eur J Pharmacol Date: 1990-05-31 Impact factor: 4.432

Review 10. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors: D J McKenna; S J Peroutka
Journal: J Neurochem Date: 1990-01 Impact factor: 5.372

8 in total

1. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.

Authors: V Pérez; J L Marco; E Fernández-Alvarez; M Unzeta
Journal: Br J Pharmacol Date: 1999-06 Impact factor: 8.739

Review 2. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors: Bryan K Yamamoto; Jamie Raudensky
Journal: J Neuroimmune Pharmacol Date: 2008-08-15 Impact factor: 4.147

Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum.

1. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.

2. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues.

3. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.

4. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.

5. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan.

6. Distinct monoamine oxidase A and B populations in primate brain.

7. The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin.

8. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis.

9. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.

Review 10. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

1. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.

Review 2. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Review 3. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Review 4. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.

Review 5. (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

6. Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons.

7. Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.

8. Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters.